Stay updated on Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page.

Latest updates to the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page
- CheckyesterdayChange DetectedA service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.SummaryDifference4%
- Check8 days agoChange DetectedThe page has been updated to version 2.16.5, and the previous version 2.16.4 has been removed from the content. Additionally, a note regarding the modernization of ClinicalTrials.gov data ingest in July 2025 has been deleted.SummaryDifference4%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference4%
- Check30 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.3%
- Check37 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.3%
- Check45 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference6%
Stay in the know with updates to Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page.